Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Other Working Capital Changes: 2022-2025

Historic Other Working Capital Changes for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$419,000.

  • Entrada Therapeutics' Other Working Capital Changes rose 97.53% to -$419,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.4 million, marking a year-over-year increase of 49.16%. This contributed to the annual value of -$119.8 million for FY2024, which is 185.59% down from last year.
  • Latest data reveals that Entrada Therapeutics reported Other Working Capital Changes of -$419,000 as of Q3 2025, which was up 45.58% from -$770,000 recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Other Working Capital Changes ranged from a high of $211.6 million in Q1 2023 and a low of -$87.0 million during Q2 2024.
  • In the last 3 years, Entrada Therapeutics' Other Working Capital Changes had a median value of -$17.0 million in 2024 and averaged $42,182.
  • Data for Entrada Therapeutics' Other Working Capital Changes shows a peak YoY increase of 12,569.58% (in 2023) and a maximum YoY decrease of 1,047.55% (in 2023) over the last 5 years.
  • Over the past 4 years, Entrada Therapeutics' Other Working Capital Changes (Quarterly) stood at $2.0 million in 2022, then tumbled by 1,047.55% to -$19.0 million in 2023, then slumped by 77.73% to -$33.7 million in 2024, then surged by 97.53% to -$419,000 in 2025.
  • Its last three reported values are -$419,000 in Q3 2025, -$770,000 for Q2 2025, and -$18.5 million during Q1 2025.